Abstract:Background/Objectives: Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic disease of the liver that symptomatically can present with pruritus and fatigue. Its established first- and second-line therapies are ursodeoxycholic acid (UDCA) and obeticholic acid (OCA) although they provide limited symptom management. Liver transplantation offers a potentially curative therapeutic option in refractory cases progressing to cirrhosis. Novel research published after the current guidelines highlights the importance of providing an up-to-date analysis of treatment options available. Methods: In this study, we conducted a literature search using Pubmed, Ovid Medline, and SCOPUS to provide a narrative review of first-line, second-line, and emerging therapies in PBC. Results: UDCA has been well established as a long-term, safe therapy within the literature although it is possible that treatment dosage can be further optimised in refractory patients. It has a favourable side effect profile. Despite improving biochemical markers, histopathological profile, and overall outcomes, up to 30–40% of patients are refractory to it. Age and sex are highlighted as independent indicators of non-responsiveness. This necessitates effective second-line therapies. Future trials could aim to investigate UDCA as a co-first-line therapy. Further supporting results for OCA were found in the interim extension trial of the seminal POISE study. The long-term phase 4 COBOLT trial is still awaiting results to further assess the complications, adherence, and potential adverse effects. It is a viable option in UDCA-refractory patients. The high incidence rate of dose-related pruritis indicates that alternative second-line options are needed. Bezafibrate is an off-label antilipemic agent that shows promise as a prospective second-line therapy option. The landmark BEZURSO trial alleviated some efficacy and safety concerns, but it remains associated with elevated serum creatinine; thus, it should be considered with caution. Other prospective second-line therapies are budesonide, triple therapy, and novel agents such as seladelpar and elafibranor. Conclusions: UDCA should remain the treatment of choice for PBC, though perhaps not as monotherapy. With further investigation, BF shows promise as a new second-line therapy alongside OCA, which it may outperform.

Sodium/bile acid co-transporter inhibitors currently in preclinical or early clinical development for the treatment of primary biliary cholangitis

Up-to-Date Snapshot of Current and Emerging Medical Therapies in Primary Biliary Cholangitis

New Treatment Paradigms in Primary Biliary Cholangitis

Impact of Pruritus on Quality of Life and Current Treatment Patterns in Patients with Primary Biliary Cholangitis

Clinical Analysis of Primary Biliary Cirrhosis: a Report of 31 Cases

Evaluation and Management of Pruritus in Primary Biliary Cholangitis

Primary biliary cholangitis: pathogenesis and therapeutic opportunities

Obeticholic acid for the treatment of primary biliary cirrhosis

Investigational farnesoid X receptor agonists for the treatment of primary biliary cholangitis

Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus

Mechanisms of pruritus in cholestasis: understanding and treating the itch

Cholestasis-Associated Pruritus and Its Pruritogens

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

New Therapies for Primary Biliary Cirrhosis

Novel therapeutic targets in primary biliary cirrhosis

Treatment in primary biliary cholangitis: Beyond ursodeoxycholic acid

Current Landscape and Evolving Therapies for Primary Biliary Cholangitis

Itching for Answers: A Comprehensive Review of Cholestatic Pruritus Treatments

S2027 Treatment Perceptions and Experiences Among Patients With PBC: Qualitative Results From the ITCH-E Study

Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products

Application of the Latest Advances in Evidence-Based Medicine in Primary Biliary Cholangitis